Table 2.

Prior lines of therapy in the metastatic setting.

Variables		N (%)
Median number of prior lines of therapy (range)		3 (1-7)
Prior targeted agents	CDK4/6 inhibitors + AI	20 (74.1%)
	CDK4/6 inhibitors + Fulvestrant	8 (29.6%)
	Everolimus + AI	11 (40.7%)
	Olaparib	2 (7.4%)
Prior clinical trial		2 (7.4%)
Prior cytotoxic therapy	Eribulin	2 (7.4%)
	Taxane	10 (37%)
	Xeloda	12 (44.4%)
	Gemcitabine	1 (3.7%)
	Platinum	1 (3.7%)
	Anthracycline	2 (7.4%)
	A/C	1 (3.7%)
Prior hormonal agents	Single-agent AI/SERD	9 (33.3%)

CDK4/6 inhibitors, cyclin-dependent kinase 4/6 inhibitors; AI, aromatase inhibitors; A/C, anthracycline and cyclophosphamide; SERD, selective estrogen receptor degrader.